ArticleJHEP reports : innovation in hepatology2026
CAR-T cells targeting activated hepatic stellate cells ameliorate liver fibrosis in mouse models.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond cancer: CAR-T cells redefining liver disease therapy.JHEP reports : innovation in hepatology · 2026Article
- Cell Therapy in Advanced Cirrhosis: From Preclinical Evidence to Clinical Application.Gastro hep advances · 2026Review
- The immunometabolic nature of MASH: framing immune cells within metabolic dysfunction.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: The transition to liver fibrosis represents a crucial and irreversible transition in chronic liver diseases, with liver fibrosis being a key driver of the progression to life-threatening complications, including cirrhosis and hepatocellular carcinoma (HCC). However, effective pharmacological therapies for liver fibrosis are lacking. Our study investigated the role of chimeric antigen receptor (CAR)-T cells in targeting and eliminating activated hepatic stellate cells (HSCs) for the treatment of liver fibrosis. Methods: We engineered CAR-T cells targeting fibroblast activation protein (FAP), a cell surface protein specifically overexpressed on activated HSCs, and evaluated their therapeutic effects on liver fibrosis across four different mouse models. Results: FAP CAR-T therapy significantly alleviated liver fibrosis across multiple etiologies ( Conclusion: Overall, our study shows that cell therapy targeting activated HSCs can ameliorate liver fibrosis and HCC, providing a novel therapeutic approach for these conditions. Impact and implications: The global disease burden of liver fibrosis remains significant. Our study provides a novel therapeutic approach, demonstrating that cell therapy targeting activated HSCs can improve liver fibrosis and HCC. These results provide an important theoretical foundation for clinicians and translational researchers. Although further studies are needed to evaluate safety and efficacy before clinical translation, this approach could ultimately offer a cell therapy option to halt disease progression in patients with advanced liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.